Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia

References

• Hughes W T, Armstrong D, Bodey G P, Bow E J, Brown A E, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730–751
   PubMed Web of Science ®Google Scholar
• Sudhoff T, Giagounidis A, Karthaus M. Serum and plasma parameters in clinical evaluation of neutropenic fever. Antibiot Chemother 2000; 50: 10–19
   PubMedGoogle Scholar
• Kern W V. Risk assessment and treatment of low-risk patients with febrile neutropenia. Clin Infect Dis 2006; 42: 533–540
   PubMed Web of Science ®Google Scholar
• Yonemori K, Kanda Y, Yamamoto R, Hamaki T, Suguro M, Chizuka A, et al. Clinical value of serial measurement of serum C-reactive protein level in neutropenic patients. Leuk Lymphoma 2001; 41: 607–614
   PubMed Web of Science ®Google Scholar
• Arber C, Passweg J R, Fluckiger U, Pless M, Gregor M, Tichelli A, et al. C-reactive protein and fever in neutropenic patients. Scand J Infect Dis 2000; 32: 515–520
   PubMed Web of Science ®Google Scholar
• Prat C, Dominguez J, Andreo F, Blanco S, Pallares A, Cuchillo F, et al. Procalcitonin and neopterin correlation with aetiology and severity of pneumonia. J Infect 2006; 52: 169–177
   PubMed Web of Science ®Google Scholar
• Erten N, Genc S, Besisik S K, Saka B, Karan M A, Tascioglu C, et al. The predictive and diagnostic values of procalcitonin and C-reactive protein for clinical outcome in febrile neutropenic patients. J Chin Med Assoc 2004; 67: 217–221
   PubMedGoogle Scholar
• Engel A, Knoll S, Kern P, Kern W V. Interleukin-8 serum levels at fever onset in patients with neutropenia predict early medical complications. Infection 2005; 33: 380–382
   PubMed Web of Science ®Google Scholar
• Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C, et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993; 341: 515–518
   PubMed Web of Science ®Google Scholar
• Oberhoffer M, Stonans I, Russwurm S, Stonane E, Vogelsang H, Junker U, et al. Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro. J Lab Clin Med 1999; 134: 49–55
   PubMed Web of Science ®Google Scholar
• Monneret G, Laroche B, Bienvenu J. Procalcitonin is not produced by circulating blood cells. Infection 1999; 27: 34–35
   PubMed Web of Science ®Google Scholar
• Marth C, Weiss G, Koza A, Reibnegger G, Daxenbichler G, Zeimet A G, et al. Increased production of immune activation marker neopterin by colony-stimulating factors in gynecological cancer patients. Int J Cancer 1994; 58: 20–23
   PubMed Web of Science ®Google Scholar
• Ascioglu S, Rex J H, de Pauw B, Bennett J E, Bille J, Crokaert F, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7–14
   PubMed Web of Science ®Google Scholar
• Muller B, White J C, Nylen E S, Snider R H, Becker K L, Habener J F, et al. Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab 2001; 86: 396–404
   PubMed Web of Science ®Google Scholar
• Engel A, Steinbach G, Kern P, Kern W V. Diagnostic value of procalcitonin serum levels in neutropenic patients with fever: comparison with interleukin-8. Scand J Infect Dis 1999; 31: 185–189
   PubMed Web of Science ®Google Scholar
• Fleischhack G, Kambeck I, Cipic D, Hasan C, Bode U. Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumour necrosis factor receptor II. Br J Haematol 2000; 111: 1093–1102
   PubMed Web of Science ®Google Scholar
• Giamarellou H, Giamarellos-Bourboulis E J, Repoussis P, Galani L, Anagnostopoulos N, et al. Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicentre study. Clin Microbiol Infect 2004; 10: 628–633
   PubMed Web of Science ®Google Scholar
• Ruokonen E, Nousiainen T, Pulkki K, Takala J. Procalcitonin concentrations in patients with neutropenic fever. Eur J Clin Microbiol Infect Dis 1999; 18: 283–285
   PubMed Web of Science ®Google Scholar
• Prat C, Dominguez J, Rodrigo C, Gimenez M, Azuara M, Jimenez O, et al. Procalcitonin, C-reactive protein and leukocyte count in children with lower respiratory tract infection. Pediatr Infect Dis J 2003; 22: 963–968
   PubMed Web of Science ®Google Scholar
• Talpaz M, Rakhit A, Rittweger K, O'Brien S, Cortes J, Fettner S, et al. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. Clin Cancer Res 2005; 11: 6247–6255
   PubMed Web of Science ®Google Scholar
• Chiang J, Gloff C A, Yoshizawa C N, Williams G J. Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin. Pharm Res 1993; 10: 567–572
   PubMed Web of Science ®Google Scholar
• de Bont E S, Vellenga E, Swaanenburg J, Kamps W. Procalcitonin: a diagnostic marker of bacterial infection in neutropenic cancer patients with fever?. Infection 2000; 28: 398–400
   PubMed Web of Science ®Google Scholar
• Abrahamsson J, Pahlman M, Mellander L. Interleukin 6, but not tumour necrosis factor-alpha, is a good predictor of severe infection in febrile neutropenic and non-neutropenic children with malignancy. Acta Paediatr 1997; 86: 1059–1064
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Venzon D, de Haas M, Chanock S J, Kuhl J. Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fc gamma receptor type III, and mannose-binding protein in febrile children with cancer and neutropenia. Clin Infect Dis 1999; 29: 414–419
   PubMed Web of Science ®Google Scholar
• Engervall P, Andersson B, Bjorkholm M. Clinical significance of serum cytokine patterns during start of fever in patients with neutropenia. Br J Haematol 1995; 91: 838–845
   PubMed Web of Science ®Google Scholar
• Sabat R, Hoflich C, Docke W D, Oppert M, Kern F, Windrich B, et al. Massive elevation of procalcitonin plasma levels in the absence of infection in kidney transplant patients treated with pan-T-cell antibodies. Intensive Care Med 2001; 27: 987–991
   PubMed Web of Science ®Google Scholar
• Klastersky J, Paesmans M, Rubenstein E, Boyer M, Elting L, Feld R, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18: 3038–3051
   PubMed Web of Science ®Google Scholar
• Meisner M. Biomarkers of sepsis: clinically useful?. Curr Opin Crit Care 2005; 11: 473–480
   PubMed Web of Science ®Google Scholar
• Persson L, Soderquist B, Engervall P, Vikerfors T, Hansson L O, Tidefelt U, et al. Assessment of systemic inflammation markers to differentiate a stable from a deteriorating clinical course in patients with febrile neutropenia. Eur J Haematol 2005; 74: 297–303
   PubMed Web of Science ®Google Scholar
• von Lilienfeld-Toal M, Schneider A, Orlopp K, Hahn-Ast C, Glasmacher A, Stuber F, et al. Change of procalcitonin predicts clinical outcome of febrile episodes in patients with hematological malignancies. Support Care Cancer 2006; 14: 1241–1245
   PubMed Web of Science ®Google Scholar
• Ortega M, Rovira M, Filella X, Almela M, Puig de la J Bellacasa, Carreras E, et al. Prospective evaluation of procalcitonin in adults with febrile neutropenia after haematopoietic stem cell transplantation. Br J Haematol 2004; 126: 372–376
   PubMed Web of Science ®Google Scholar
• Christofilopoulou S, Charvalos E, Petrikkos G. Could procalcitonin be a predictive biological marker in systemic fungal infections? Study of 14 cases. Eur J Intern Med 2002; 13: 493–495
   PubMedGoogle Scholar
• Dornbusch H J, Strenger V, Kerbl R, Lackner H, Schwinger W, Sovinz P, et al. Procalcitonin and C-reactive protein do not discriminate between febrile reaction to anti-T-lymphocyte antibodies and gram-negative sepsis. Bone Marrow Transplant 2003; 32: 941–945
   PubMed Web of Science ®Google Scholar
• Ortega M, Rovira M, Filella X, Martinez J, Almela M, Puig J, et al. Prospective evaluation of procalcitonin in adults with non-neutropenic fever after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 37: 499–502
   PubMed Web of Science ®Google Scholar
• Christ-Crain M, Muller B., et al. Procalcitonin in bacterial infections – hype, hope, more or less?. Swiss Med Wkly 2005; 135: 451–460
   PubMed Web of Science ®Google Scholar